Iris K. Minichmayr

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 462 citations · Full text

Drug Safety, Adverse Drug Reactions, Pharmacoepidemiology +9

Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study

L. Ehmann, Michael Zöller, Iris K. Minichmayr et al. · Critical Care · 2017 · 72 citations · Full text

Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model

Iris K. Minichmayr, Jason A. Roberts, Otto Frey et al. · Journal of Antimicrobial Chemotherapy · 2018 · 72 citations · Full text

Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis

L. Ehmann, Michael Zöller, Iris K. Minichmayr et al. · International Journal of Antimicrobial Agents · 2019 · 69 citations

Therapeutic Drug Monitoring, Ill Patients, Dosing Algorithm +8

Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients

Iris K. Minichmayr, André Schaeftlein, Joseph L. Kuti et al. · Clinical Pharmacokinetics · 2016 · 63 citations

Clinical Determinants, Critically Ill Patients, Critical Care Medicine +9